These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16091471

  • 1. NKG2D-independent suppression of T cell proliferation by H60 and MICA.
    Kriegeskorte AK, Gebhardt FE, Porcellini S, Schiemann M, Stemberger C, Franz TJ, Huster KM, Carayannopoulos LN, Yokoyama WM, Colonna M, Siccardi AG, Bauer S, Busch DH.
    Proc Natl Acad Sci U S A; 2005 Aug 16; 102(33):11805-10. PubMed ID: 16091471
    [Abstract] [Full Text] [Related]

  • 2. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
    Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.
    Nature; 2001 Sep 13; 413(6852):165-71. PubMed ID: 11557981
    [Abstract] [Full Text] [Related]

  • 3. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
    O'Callaghan CA, Cerwenka A, Willcox BE, Lanier LL, Bjorkman PJ.
    Immunity; 2001 Aug 13; 15(2):201-11. PubMed ID: 11520456
    [Abstract] [Full Text] [Related]

  • 4. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
    Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD.
    J Immunol; 2006 Jan 15; 176(2):905-13. PubMed ID: 16393975
    [Abstract] [Full Text] [Related]

  • 5. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A, Hsia JK, Hsiung MY, Raulet DH.
    Eur J Immunol; 2003 Feb 15; 33(2):381-91. PubMed ID: 12645935
    [Abstract] [Full Text] [Related]

  • 6. EAE tolerance induction with Hsp70-peptide complexes depends on H60 and NKG2D activity.
    Galazka G, Jurewicz A, Orlowski W, Stasiolek M, Brosnan CF, Raine CS, Selmaj K.
    J Immunol; 2007 Oct 01; 179(7):4503-12. PubMed ID: 17878346
    [Abstract] [Full Text] [Related]

  • 7. Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D.
    Cerwenka A, O'Callaghan CA, Hamerman JA, Yadav R, Ajayi W, Roopenian DC, Joyce S, Lanier LL.
    J Immunol; 2002 Apr 01; 168(7):3131-4. PubMed ID: 11907062
    [Abstract] [Full Text] [Related]

  • 8. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
    Ito Y, Kanai T, Totsuka T, Okamoto R, Tsuchiya K, Nemoto Y, Yoshioka A, Tomita T, Nagaishi T, Sakamoto N, Sakanishi T, Okumura K, Yagita H, Watanabe M.
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan 01; 294(1):G199-207. PubMed ID: 17962357
    [Abstract] [Full Text] [Related]

  • 9. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
    Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lémann M, Mayer L, Toubert A.
    Gastroenterology; 2007 Jun 01; 132(7):2346-58. PubMed ID: 17570210
    [Abstract] [Full Text] [Related]

  • 10. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D.
    Takada A, Yoshida S, Kajikawa M, Miyatake Y, Tomaru U, Sakai M, Chiba H, Maenaka K, Kohda D, Fugo K, Kasahara M.
    J Immunol; 2008 Feb 01; 180(3):1678-85. PubMed ID: 18209064
    [Abstract] [Full Text] [Related]

  • 11. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V.
    Neoplasia; 2004 Feb 01; 6(5):558-68. PubMed ID: 15548365
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A.
    J Immunol; 2005 Jul 15; 175(2):720-9. PubMed ID: 16002667
    [Abstract] [Full Text] [Related]

  • 14. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.
    Cancer Res; 2005 Jul 15; 65(14):6321-9. PubMed ID: 16024634
    [Abstract] [Full Text] [Related]

  • 15. Strategies for target cell recognition by natural killer cells.
    Diefenbach A, Raulet DH.
    Immunol Rev; 2001 Jun 15; 181():170-84. PubMed ID: 11513138
    [Abstract] [Full Text] [Related]

  • 16. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
    Teng MW, Kershaw MH, Hayakawa Y, Cerutti L, Jane SM, Darcy PK, Smyth MJ.
    J Biol Chem; 2005 Nov 18; 280(46):38235-41. PubMed ID: 16169855
    [Abstract] [Full Text] [Related]

  • 17. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
    Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL.
    J Immunol; 2005 Aug 15; 175(4):2167-73. PubMed ID: 16081783
    [Abstract] [Full Text] [Related]

  • 18. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
    Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T.
    Science; 1999 Jul 30; 285(5428):727-9. PubMed ID: 10426993
    [Abstract] [Full Text] [Related]

  • 19. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H, Kim J, Cosman D, Choi I.
    Cell Immunol; 2006 Jan 30; 239(1):22-30. PubMed ID: 16630603
    [Abstract] [Full Text] [Related]

  • 20. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection.
    Feng L, Ke N, Ye Z, Guo Y, Li S, Li Q, Li Y.
    Transplant Proc; 2009 Dec 30; 41(10):4332-9. PubMed ID: 20005394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.